You are here: Industry Insights > Samsung

News List

Samsung Biologics Acquires Full Ownership of Samsung Bioepis contractpharma
January 29, 2022
Buys out Biogen’s stake in the joint venture for $2.3 billion.
Moderna Spikevax Receives Marketing Authorization in Korea contractpharma
December 16, 2021
The Moderna COVID-19 vaccine manufactured at Samsung Biologics’ local production facilities can be distributed in Korea and exported to other countries.
GreenLight Biosciences, Samsung Biologics Partner to Advance New RNA Covid Vax ContractPharma
November 30, 2021
GreenLight Biosciences, a Biotechnology company dedicated to making ribonucleic acid ( RNA ) products affordable and accessible for human health and agriculture, and Samsung Biologics...
GreenLight and Samsung Biologics to produce Covid-19 vaccines Pharmaceutical-Technology
November 26, 2021
GreenLight Biosciences and Samsung Biologics have signed a collaboration agreement for manufacturing messenger ribonucleic acid (mRNA) Covid-19 vaccines.
Samsung Biologics, Kineta Enter Development and Manufacturing Agreement contractpharma
July 21, 2021
Samsung's San Francisco R&D center and South Korea headquarters to offer end-to-end CDMO service for anti-VISTA antibody immunotherapy.
Samsung Biologics Issues Its First Annual Sustainability Report prnasia
June 25, 2021
Samsung Biologics, the world's leading contract development and manufacturing organization (CDMO), published its first annual sustainability report, consolidating the company's policies for an enhanced ESG management system and related plans.
Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate prnasia
June 03, 2021
Samsung Biologics, the world's leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment proteins. Under the ...
Samsung Biologics Expands Vaccine Manufacturing Capabilities contractpharma
June 02, 2021
Samsung Biologics, a global CDMO providing end-to-end contract development and manufacturing services, unveiled plans to add mRNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within ...
Samsung Biologics to add mRNA vaccine drug substance manufacturing suite to expand portfolio of services prnasia
June 01, 2021
Samsung Biologics announced its plans to add mRNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within the earlier part of the year in 2022.
Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine prnasia
May 24, 2021
Moderna and Samsung Biologics announced a Manufacturing Services and Supply Agreement in which Samsung Biologics will provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna's COVID-19 vaccine.

Previous page 1 2 3 4 Next page